Strong trial data has rewritten Cosmo’s prospects, but the real test lies ahead as regulators, partners and patients decide ...

Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its ...

A new Nipah virus vaccine has proven safe and capable of generating a strong immune response, according to findings published ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion ...

Palisade extended its winning streak to a fourth straight day on Wednesday, jumping 5.26 percent to close at $2.20 apiece as ...

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

That morning, Edgewise presented interim data from its ongoing Phase 2 clinical trial of EDG-7500, an investigational drug targeting hypertrophic cardiomyopathy (HCM). This is a genetic heart ...

Oramed (ORMP) targets a new patient subset after FDA setback. Learn how promising trials may revive its protein oral delivery ...

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic ...

Adjuvant carboplatin added to standard anthracycline/taxane chemotherapy significantly improves outcomes in early ...

Clinical trials continue to shape metastatic breast cancer treatment, making therapies safer, more tolerable, and more ...